Investigating the Role of DNMT Inhibitor CM-272 Through p21-Mediated Apoptosis in SK-N-SH Neuroblastoma Cells

Investigating the Role of DNMT Inhibitor CM-272 Through p21-Mediated Apoptosis in SK-N-SH Neuroblastoma Cells

Alvin Sherman Library

Neuroblastoma is a pediatric malignancy originating from neural crest cells, which can manifest the disease anywhere along the sympathetic nervous system. Evidence suggests that epigenetic modifications may trigger cell cycle arrest and induce apoptosis, providing a potential therapeutic avenue for such cancers.

This study investigates whether CM-272, a DNMT-1 inhibitor, promotes histone acetylation and upregulates p21 through a p53-independent pathway, ultimately triggering cell cycle arrest and apoptosis cell death via caspase-mediated mechanisms in SK-N-SH cells. To assess the effects of CM272, we conducted qRT-PCR to evaluate the DNMT-1 gene expression levels and performed western blot analyses to examine key proteins, including p21, p53, acetyl-histone-H3, acetyl-histone-H4, PARP.

qRT-PCR results revealed a significant downregulation of DNMT-1 expression in the CM-272-treated groups compared to controls. Additionally, CDKN1A mRNA levels, which encode the cell cycle regulator p21, were upregulated following CM-272 treatment, suggesting a possible role in inducing cell cycle arrest and halting tumor progression. Western blot analysis further demonstrated that CM-272 treatment elevated p21 levels in a p53-independent manner and induced apoptosis through PARP cleavage. In conclusion, our findings indicate that CM-272 treatment effectively downregulates DNMT-1 expression while upregulating p21 levels, leading to cell cycle arrest and apoptosis. The ability of CM272 to induce these effects via a p53-independent mechanism underscores its potential as a promising therapeutic agent for treating neuroblastoma, targeting critical regulators of the cell cycle and apoptosis pathways.

(This project was supported by the National Pediatric Cancer Foundation (NPCF), and The Royal Dames of Cancer Research Inc. Ft. Lauderdale, Florida)